Zynex Inc. ($ZYXI, formerly $ZYXIQ) faces a major securities class action lawsuit filed by the Hagens Berman law firm, stemming from what prosecutors allege was a systematic overbilling scheme that has decimated shareholder value and triggered the company's complete collapse into bankruptcy.
The litigation, covering a period from February 25, 2021, through December 15, 2025, targets Zynex and its former executives over allegations that the company engaged in excessive medical supply shipments designed to artificially inflate billings to government and private healthcare payors. The lawsuit represents the latest chapter in a dramatic downfall that has already resulted in criminal indictments, a substantial federal settlement, and the company's transition from a Nasdaq-listed public company to a shell entity in Chapter 11 bankruptcy protection.
The Unraveling of a Once-Traded Company
The collapse of Zynex sent shockwaves through its investor base after years of operating as a publicly traded medical device and supplies company. The company's troubles began surfacing when Tricare, the healthcare system serving military families and retirees, suspended payments to the company—a significant blow given the importance of government contracts to medical supply businesses.
Following the payment suspension, federal authorities moved swiftly. Former CEO Thomas Sandgaard and COO Anna Lucsok faced criminal indictments related to the alleged billing scheme. The company subsequently negotiated a settlement with federal prosecutors that included an $85 million forfeiture, a staggering sum that underscored the scale of the alleged misconduct.
These developments triggered a cascading series of catastrophic consequences for shareholders:
- Chapter 11 bankruptcy filing: The company sought bankruptcy protection as its financial position became untenable
- Nasdaq delisting: Loss of public market status signaled regulatory and financial distress
- Near-total shareholder losses: Common equity holders experienced near-complete wipeout of their investments
- Class action litigation: The Hagens Berman lawsuit now seeks damages on behalf of affected shareholders
Market Context and Industry Implications
The Zynex collapse occurs within a broader healthcare industry landscape where billing practices have come under heightened scrutiny from federal authorities. The medical supplies and home health equipment sector—which Zynex operated within—has become a particular focus for fraud prevention efforts, as the federal government seeks to protect Medicare, Medicaid, and Tricare from overbilling schemes.
Government healthcare programs represent enormous payment streams, making them prime targets for sophisticated billing fraud. When companies systematize overbilling through mechanisms like excessive shipments, the financial impact multiplies quickly. The alleged scheme's timing—spanning nearly five years—suggests potential exposure of hundreds of millions in claimed inappropriate billings.
The $85 million forfeiture settlement indicates prosecutors viewed the case as serious enough to pursue both criminal and civil remedies simultaneously. This dual approach, combined with the class action lawsuit, represents the multi-pronged enforcement strategy regulators increasingly employ against healthcare fraud.
For investors in medical supplies and home health companies, the Zynex case serves as a cautionary tale about the regulatory risks inherent in government-dependent businesses. Companies relying heavily on Medicare, Medicaid, or Tricare payments face intense scrutiny, and billing practices that might appear aggressive in the private sector can trigger federal investigations when government dollars are involved.
Investor Implications and Shareholder Recovery Prospects
For shareholders who held $ZYXI or $ZYXIQ during the relevant period, the news presents a grim but important reality. The combination of bankruptcy and criminal/civil settlements typically leaves common equity holders in a severely disadvantaged position in the capital structure. Bankruptcy courts prioritize secured creditors and bondholders before addressing equity claims, and in cases involving substantial fraud forfeitures, equity recovery prospects diminish further.
The Hagens Berman class action lawsuit offers a potential avenue for recovery, but its success depends on several factors:
- Proof of misleading statements: Demonstrating that company executives made material misrepresentations about billing practices and financial health
- Causation: Linking specific statements to shareholder losses
- Insurance coverage: Whether the company maintained directors and officers liability insurance that could fund settlements
- Bankruptcy proceedings: How the class action claim ranks against other liabilities in the Chapter 11 process
Historically, securities class actions in bankruptcy contexts often result in modest recoveries for shareholders. The presence of both criminal and civil government settlements may actually complicate matters, as forfeiture obligations typically have priority status.
Investors who purchased Zynex shares during the alleged scheme period—particularly those who bought based on earnings reports or management guidance that may have relied on inflated billing figures—represent the lawsuit's target class. The case highlights why due diligence on billing practices and government payment relationships proves critical when evaluating healthcare services companies.
Looking Forward
The Zynex saga underscores the heightened enforcement environment surrounding healthcare billing practices and government contractor relationships. For the broader medical supplies industry, this case reinforces that federal authorities will pursue both criminal and civil remedies against companies employing systematic overbilling schemes, and that investors in such companies face not only business losses but potential legal action against company leadership.
As the securities class action proceeds through the courts and the company continues through bankruptcy restructuring, shareholders face the difficult reality that their investment in Zynex has largely evaporated. The litigation represents one final attempt to recover some losses, though the broader message for healthcare investors is clear: governance failures and billing misconduct carry devastating consequences for shareholder value.